Refractory Multi-Inflammatory Syndrome in a Two Weeks Old Neonate with COVID-19 Treated Successfully with Intravenous Immunoglobulin, Steroids and Anakinra

Authors: Magboul S*, Khalil A, Alshami A, Alaido M, Ellithy K, AlMaslamani E, Alhothi A, AL Amri M and Hassan M

DOI: 10.23880/oajmb-16000176

Volume 5, Issue 4

Abstract

Background: World Health Organization (WHO) and other Health officials alert clinicians about a rare but severe inflammatory condition seen in children and linked to Corona Virus Disease 2019(COVID-19). The WHO is describing the condition as a multisystem inflammatory syndrome in children (MIS-C) and is recommending clinicians to report those cases to get a better understanding of the disease and clinicians can learn more. Case Presentation: We are reporting the clinical course of the youngest case of COVID-19 related MIS-c; a two-week-old term neonate with COVID-19 infection and features suggestive of MIS-C, managed with intravenous immunoglobulin (IVIG), pulse steroid, and interleukin-1 inhibitor (Anakinra). By reviewing the literature, our baby is the first neonatal case who has been diagnosed with MIS-C. Conclusion: COVID-19 infections in pediatrics are likely to present with a mild course; however, some may develop a hyperinflammatory syndrome. Pediatricians should be aware of such presentation, the clinical course, the management modalities, and inform parents and caregivers about common signs and symptoms. Anakinra may consider as effective second agent in (IVIG and steroid-refractory pediatric cases).

Keywords: Neonatal COVID-19; SARS-Cov-2; Multisystem Inflammatory Syndrome of Children MIS-C; Pediatric MultiSystem Inflammatory Syndrome PIMS

View PDF